Effect of multimodal training on serotonin and dopamine levels in patients with Parkinson's disease.

The effect of 12 weeks of multimodal exercises on the level of serotonin, dopamine and neurotrophic and functional factors in patients with Parkinson's disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241008063289N1

Enrollment

Registered

2025-01-24

Start date

2025-01-20

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multimodal training, BDNF? CDNF, dopamine, serotonin.

Interventions

Intervention 1: Intervention group: receives multimodal exercises. Intervention 2: Control group: They will not receive any intervention, but physical fitness tests and examination of the study's targ

Eligibility

Sex/Gender

Female

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Female gender minimum age 50 years and maximum age 70 years Lack of structural abnormalities including structures that limit high-intensity exercise such as musculoskeletal (musculoskeletal) abnormalities Lack of chronic diseases controlled by medication Avoid taking broad-spectrum antibiotics for at least 3 weeks. Not taking any type of psychological (neuro) medication.

Exclusion criteria

Exclusion criteria: personal lack of consent to receive samples and participate in the intervention Injury or damage that prevents the subject from exercising

Design outcomes

Primary

Measure	Time frame
Serotonin. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum serotonin kit.;CDNF. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum CDNF kit.;BDNF. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum BDNF kit.;Dopamine. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum dopamine kit.	—

Measure

Time frame

Serotonin. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum serotonin kit.;CDNF. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum CDNF kit.;BDNF. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum BDNF kit.;Dopamine. Timepoint: At the beginning and end of 12 weeks of study. Method of measurement: Serum dopamine kit.

—

Secondary

Measure	Time frame
Body composition. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Body analysis device made in South Korea.;Strength. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Muscular strength (arm curl test) and Lower body muscle strength test(chair stand test).;Cardiorespiratory endurance. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Rockport One Mile Walk Test.;Quality of life. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Jenkinson questionnaire.	—

Measure

Time frame

Body composition. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Body analysis device made in South Korea.;Strength. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Muscular strength (arm curl test) and Lower body muscle strength test(chair stand test).;Cardiorespiratory endurance. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Rockport One Mile Walk Test.;Quality of life. Timepoint: At the beginning and end of the study after 12 weeks. Method of measurement: Jenkinson questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhosro Jalali Dehkordi

Islamic Azad University

khosrojalali@gmail.com+98 31335002352

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026